Argenx is a hold due to limited catalysts in 2025, a rich valuation and clinical risk around label expansion. Read more about ...

Rheumatologists and cardiologists have long co-managed patients out of necessity and without much formal collaboration or ...

The dosing schedule of NKX019 was harmonized across all four clinical trials in the fourth quarter of 2024. Patients receive NKX019 on Days 0, 3 and 7 following single-agent lymphodepletion with ...

Ntrust-1 is enrolling patients with lupus nephritis. Ntrust-2 is enrolling patients with systemic sclerosis (scleroderma), idiopathic inflammatory myopathy (myositis), or ANCA-associated ...

CRISPR Therapeutics poised for growth with international potential and clinical assets. Read why I rate CRSP stock a Strong ...

Varied approaches to remote patient monitoring are in development to close care gaps between patients and rheumatologists, ...

as well as trials in cutaneous lupus erythematosus and myositis. Brian Hilberdink, Boehringer Ingelheim's new Head of US Human Pharma, fielded questions on a variety of hot topics from the Reuters ...

Corient Private Wealth LLC grew its holdings in shares of argenx SE (NASDAQ:ARGX – Free Report) by 14.7% in the 4th quarter, ...

Farther Finance Advisors LLC grew its stake in shares of argenx SE (NASDAQ:ARGX – Free Report) by 38.2% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 76 shares ...